This article is for men with metastatic castration-resistant prostate cancer (mCRPC) who have completed treatment cycles of lutetium Lu-177 vipivotide tetraxetan and are asking: what happens next? The final infusion can feel like a strange pause. You have been through a structured treatment schedule, and now the watching and waiting begins. Understanding what your team is tracking, and when to talk about what comes next, puts you in a better position to guide your own care.
Lu-177 PSMA radioligand therapy targets PSMA (prostate-specific membrane antigen) proteins on cancer cells and delivers radiation directly to them. Most treatment protocols involve four to six cycles, spaced about six weeks apart. Once those cycles end, monitoring takes center stage.
What Does Your Team Watch After Lu-177 PSMA Cycles
Your follow-up care covers seven key areas:
- PSA (prostate-specific antigen) level - checked at every follow-up visit
- Full blood count - hemoglobin, platelets, and white blood cells
- Kidney function - creatinine and estimated GFR (glomerular filtration rate)
- Liver function tests
- PSMA-PET/CT imaging - typically scheduled after your complete treatment course
- Symptom review - bone pain, fatigue, dry mouth, and any new complaints
- Quality-of-life check - how you are functioning day to day
How Long Does Monitoring Continue?
Monitoring does not end with your last infusion. The radioactive lutetium-177 continues to work and clear from your body for several weeks after each cycle. Your kidneys filter it out through your urine, and your care team watches kidney and blood markers carefully during this period.
In most protocols, a follow-up visit is scheduled four to six weeks after the final cycle. After that, visits typically happen every two to three months in the first year. Your team will set the exact schedule based on your response, your overall health, and whether any concerns arose during treatment. This schedule may feel less intense than the treatment phase, but it is just as important.
What Your PSA Tells You - and What It Does Not
PSA is the marker your team will discuss at every visit. A decline of 50% or more from your starting level often indicates meaningful response. Clinical studies of lutetium Lu-177 vipivotide tetraxetan showed that a significant portion of patients achieve this kind of PSA decline during treatment.
Early PSA changes, as soon as four weeks after the first cycle, may predict long-term response and overall survival in mCRPC patients receiving PSMA radioligand therapy. This is why your team may track PSA at relatively frequent intervals early in the treatment course, not just at the end.
A few important things to know about PSA after treatment:
- PSA can rise briefly at the start of treatment before it falls. This is sometimes called a PSA flare and does not mean treatment is failing.
- PSA can fall while some lesions still grow on imaging, or rise while others shrink. A single number is not the full picture.
- Your team will look at the trend across several visits, not just one result.
For a fuller explanation of what each PSA reading means during and after treatment, see our in-depth guide to PSA levels during Lu-177 PSMA therapy and what they mean for your treatment.
What Scans Come After Your Last Cycle?
Most protocols include a PSMA-PET/CT scan after completing treatment. This scan uses a radiotracer - usually gallium-68 PSMA - to show where PSMA-positive cancer cells remain and where disease may have resolved. It tells your team which lesions responded, whether any new ones have appeared, and whether PSMA expression on your tumor cells has changed since your pre-treatment baseline scan.
The Joint EANM/SNMMI procedure guideline for Lu-177 PSMA radioligand therapy states that your team primarily assesses response by comparing baseline to follow-up PSMA-PET/CT imaging alongside PSA changes. Some specialized centers also use SPECT/CT imaging taken 24 to 48 hours after each infusion to measure how well the therapy reached each tumor site - a process called dosimetry - and this may inform decisions about further cycles.
Your team may also order conventional CT, a bone scan, or MRI if there are lesions in soft tissue or lymph nodes, or when PSMA imaging alone is unclear.
What Blood Tests Are Protecting During Follow-Up
Lu-177 PSMA targets cancer cells, but some healthy tissue is exposed during and after treatment - particularly the kidneys, salivary glands, and bone marrow. Blood monitoring after your last cycle is how your team catches any delayed effects early, before they affect your ability to start the next treatment.
Key values your team watches:
- Hemoglobin - low levels (anemia) cause fatigue and reduce your ability to tolerate further treatment
- Platelets - low levels (thrombocytopenia) raise bleeding risk
- Neutrophils - low levels (neutropenia) increase infection risk
- Creatinine and eGFR - measures of kidney function; the kidneys carry some radiation exposure as they filter lutetium-177 from the body
- Liver enzymes - a baseline check on liver health at each visit
A study on renal safety of Lu-177 PSMA-617 in patients with compromised baseline kidney function shows that most patients with mild-to-moderate pre-existing kidney impairment experience no significant worsening during or after treatment. Monitoring remains essential to catch any exceptions early and act on them.
Many men with mCRPC are also on long-term androgen deprivation therapy (ADT), which reduces bone density over time. This effect is separate from the direct effects of Lu-177. If you are not already on bone-protective medication, the post-treatment follow-up period is a good time to raise this with your oncologist.
Managing Fatigue in the Weeks After Your Final Cycle
Tiredness in the weeks following your last Lu-177 PSMA infusion is common. The treatment itself, combined with ongoing hormone therapy and the physical weight of living with advanced prostate cancer, all contribute. For most men, energy levels gradually improve over six to twelve weeks after the final cycle.
If fatigue is severe or doesn't improve, tell your care team - it may point to anemia or low blood counts that need specific attention. For a full explanation of what drives fatigue after radioligand therapy and practical steps to support recovery, see our guide to managing fatigue during and after Lu-177 PSMA therapy.
When Is It Time to Talk About What Comes Next?
The follow-up scan and blood results after your last cycle are the natural trigger for a conversation about next steps. Three broad scenarios come up:
Scenario 1 - Good response, disease stable. PSA has fallen significantly and scans show reduced or stable disease. Your team may recommend a monitoring period without immediate new treatment - sometimes called active surveillance of response. The focus shifts to maintaining your quality of life and watching for early signs of further disease activity.
Scenario 2 - Mixed or partial response. Some lesions responded, others did not. Your team may explore whether additional Lu-177 PSMA cycles are appropriate, or whether a different approach is needed for lesions that didn't respond. Clinical studies show that a second course of Lu-177 PSMA therapy may be safe and beneficial for patients who responded well to the first course and retain adequate PSMA expression. Our detailed article on retreatment eligibility after your first Lu-177 PSMA course walks through what to ask and what to expect.
Scenario 3 - Progression. PSA continues to rise or new lesions appear on imaging during or shortly after treatment. This is when next-line therapy options come onto the table most urgently. Moving quickly from this conversation to a next step matters.
What Options Might Come After Lu-177 PSMA
mCRPC treatment continues to develop and options vary depending on what you have received before, your current performance status, and the molecular features of your tumor. Your oncologist is the right person to guide which options apply to your specific case. That said, options sometimes discussed in the post-Lu-177 setting - depending on prior treatment history - may include further taxane chemotherapy, PARP inhibitors (particularly when DNA repair gene mutations are present), or changes to hormonal therapies. Your team may also discuss whether another course of Lu-177 PSMA fits your situation.
Clinical trials are another option worth raising at this stage. Trials specifically designed for mCRPC patients who have received radioligand therapy are ongoing. You can search for open studies at the National Cancer Institute clinical trials registry.
If you are not sure whether your team has considered all current options for your stage and prior treatment history, a specialist nuclear medicine review can be valuable.
How to Build a Follow-Up Care Plan That Works for You
A good follow-up care plan should be written down and agreed with your team before you leave the clinic after your last cycle. It should be clear about who to call if something changes between visits. Ask your team to confirm the following before you go home:
- When is my next blood test, and which values is the team watching most closely?
- When will my follow-up PSMA-PET/CT scan be scheduled, and where?
- Who do I contact if I develop new or worsening symptoms between visits?
- What PSA level or imaging finding would trigger a conversation about next-line treatment?
- Are there any activities or medications to avoid while my kidneys continue clearing the radiotracer?
- Should I be on bone-protective medication, and when was my vitamin D level last checked?
If you received treatment abroad, your follow-up will typically transfer back to your home oncologist. Before you travel home, ask your treating center for a full written summary: the number of cycles received, total activity administered, your PSA trajectory throughout treatment, any side effects that were observed, and a recommended follow-up schedule. Share this document with your home team as soon as possible so monitoring can continue without a gap in the handoff.
When to Talk to Your Doctor
Contact your oncology team promptly if you notice any of the following after completing your Lu-177 PSMA cycles: new or worsening bone pain, fever or signs of infection such as chills or unusual sweating, unexpected bruising or bleeding, significant fatigue that doesn't improve over several weeks, changes in urinary function, or swelling in your legs. These symptoms may or may not be related to your treatment, but your team needs to know so they can act quickly if something requires attention.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
How soon after my last Lu-177 PSMA cycle will I know if the treatment worked?
Most teams schedule a formal response review - including a PSMA-PET/CT scan and blood tests - four to six weeks after the final cycle. However, your team may also look at PSA trends at earlier visits, since research suggests that PSA changes as early as four weeks after the first cycle may predict longer-term response. A single follow-up result rarely tells the whole story; your team will review trends across several appointments before drawing firm conclusions.
What PSA change tells me Lu-177 PSMA worked?
A decline of 50% or more from your starting PSA level is commonly used as a marker of meaningful response. However, PSA can sometimes rise briefly early in treatment - called a PSA flare - before falling, and PSA can decline while some lesions still progress on scans. Your team will look at PSA alongside imaging results and your symptoms to get a complete picture rather than relying on PSA alone.
Can I have a second course of Lu-177 PSMA if my cancer becomes active again after a good response?
Yes, retreatment - sometimes called rechallenge - may be an option for patients who responded well to their first course and whose cancer still shows high PSMA expression on a repeat PET scan. Published research has shown that a second course may be safe and can provide further disease control in selected patients. Eligibility for retreatment is assessed case by case by your oncology and nuclear-medicine team, taking into account your current blood counts, kidney function, and overall health.
What happens if my PSA keeps rising after all my Lu-177 PSMA cycles are done?
A rising PSA after completing your treatment course signals that your cancer is progressing and that a conversation about next-line therapy is needed. Your team will review your imaging, your prior treatment history, and any molecular features of your cancer - such as DNA repair gene mutations - to discuss which options may be most appropriate. The choices vary depending on what you have had before, so your oncologist is the right person to walk through the options specific to your case.
What scans will I need after finishing Lu-177 PSMA therapy?
Most protocols include a PSMA-PET/CT scan using a gallium-68 PSMA tracer after completing a full course of treatment. This scan compares your current disease picture to the baseline scan done before treatment started. Depending on your situation, your team may also order a conventional CT scan, bone scan, or MRI to evaluate specific sites. The exact timing and type of follow-up imaging is determined by your oncology team based on your individual case.
How long does fatigue last after Lu-177 PSMA treatment ends?
Fatigue is common in the weeks after Lu-177 PSMA therapy and tends to be most noticeable in the first two to four weeks after the final cycle. For most patients, energy levels gradually improve over six to twelve weeks. If fatigue is severe, worsens rather than improves, or is accompanied by other symptoms, let your care team know - anemia or low blood counts can contribute to persistent fatigue and may need specific treatment.